Respiratory Generics: Big Potential But A Tough Market To Crack
Executive SummaryWith GlaxoSmithKline's blockbuster asthma drug Advair facing patent expiration later this year, generic drug makers like Teva and Sandoz are looking to pounce on the opportunity
You may also be interested in...
Financings Of The Fortnight: In The Aftermath Of Facebook IPO, Kythera Steps Up, TVAX And Cancer Genetics Back Off
Plus news on recent financing activity by TVM Capital, Royalty Pharma, Prosonix and Sangart.
Prosonix receives an extra $9 million for its Series B round as it changes business strategy from contract research to the development of generic respiratory products, based on a novel particle-engineering technology for inhaled powders.
Jeff George, global head of Sandoz, talks about enoxaparin, a commitment to quality manufacturing, and investing in differentiated products.